SMSLIFE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
SMS Lifesciences India soars; facility gets US FDA clearance
** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)
** A VAI classification implies facility won't face any regulatory action
** SMSL, which jumped 17% prior to the news, held gains after company disclosure
** Stock set for best day since August 12, 2024
** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs
** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg
** YTD, SMSL gains 13.4%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)
** A VAI classification implies facility won't face any regulatory action
** SMSL, which jumped 17% prior to the news, held gains after company disclosure
** Stock set for best day since August 12, 2024
** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs
** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg
** YTD, SMSL gains 13.4%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does SMS Lifesciences do?
SMS Lifesciences India is involved in the manufacturing, buying, selling, and consultancy of Organic & Inorganic Chemicals, Pharmaceuticals, API, and Intermediates.
Who are the competitors of SMS Lifesciences?
SMS Lifesciences major competitors are Everest Organics, Nectar Lifesciences, Bal Pharma, Smruthi Organics, Tyche Inds, Mangalam Drugs&Org., Lasa Supergenerics. Market Cap of SMS Lifesciences is ₹338 Crs. While the median market cap of its peers are ₹151 Crs.
Is SMS Lifesciences financially stable compared to its competitors?
SMS Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does SMS Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. SMS Lifesciences latest dividend payout ratio is 4.99% and 3yr average dividend payout ratio is 3.58%
How has SMS Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable, Short Term Loans & Advances
How strong is SMS Lifesciences balance sheet?
Balance sheet of SMS Lifesciences is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of SMS Lifesciences improving?
The profit is oscillating. The profit of SMS Lifesciences is ₹18.73 Crs for TTM, ₹9.09 Crs for Mar 2024 and ₹11.46 Crs for Mar 2023.
Is the debt of SMS Lifesciences increasing or decreasing?
The net debt of SMS Lifesciences is decreasing. Latest net debt of SMS Lifesciences is ₹82.51 Crs as of Mar-25. This is less than Mar-24 when it was ₹94.79 Crs.
Is SMS Lifesciences stock expensive?
SMS Lifesciences is not expensive. Latest PE of SMS Lifesciences is 16.83, while 3 year average PE is 17.91. Also latest EV/EBITDA of SMS Lifesciences is 9.34 while 3yr average is 9.73.
Has the share price of SMS Lifesciences grown faster than its competition?
SMS Lifesciences has given better returns compared to its competitors. SMS Lifesciences has grown at ~15.21% over the last 7yrs while peers have grown at a median rate of 3.69%
Is the promoter bullish about SMS Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in SMS Lifesciences is 71.41% and last quarter promoter holding is 71.41%.
Are mutual funds buying/selling SMS Lifesciences?
There is Insufficient data to gauge this.